Biblio
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024;11(4):e287-e298.
The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep. 2019.
. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021.
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2019.
Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid. 2023;2(6):EVIDoa2200339.
Accelerated Phase of Myeloproliferative Neoplasms. Acta Haematol. 2021:1-16.
.